Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label ASP5541 study in advanced prostate cancer
2024-517653-27-00Phase 2Authorised
- Sponsor
- Astellas Pharma
- Start
- Dec 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of abiraterone decanoate in prostate cancer (PCa) (3 cohorts), sponsored by Astellas Pharma. Planned start Dec 2025; status: authorised.
02
Drugs
abiraterone decanoate
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-517653-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517653-27-00.